Glucotrack GAAP EPS of -$4.64

* Glucotrack press release [https://seekingalpha.com/pr/20307323-glucotrack-reports-third-quarter-2025-financial-results-and-provides-update-on-recent] (GCTK [https://seekingalpha.com/symbol/GCTK]): Q3 GAAP EPS of -$4.64.
* Research and development expenses were $3.2 million for the three months ended September 30, 2025, compared to $2.1 million for the same period in 2024. The increase was primarily due to increased product and manufacturing development costs related to the development of the Glucotrack CBGM Product.
*
Marketing and general and administrative expense were $1.1 million for the three months ended September 30, 2025, compared to $1.2 million for the same period in 2024. The decrease is primarily attributable to reduced board of director and legal fees, offset by increased professional fees, and personnel costs.

* Shares -0.88% AH.

MORE ON GLUCOTRACK

* Seeking Alpha’s Quant Rating on Glucotrack [https://seekingalpha.com/symbol/GCTK/ratings/quant-ratings]
* Financial information for Glucotrack [https://seekingalpha.com/symbol/GCTK/income-statement]